TY - JOUR
T1 - reirradiation for isolated local recurrence of prostate cancer
T2 - Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBrT)
AU - Jereczek-Fossa, Barbara Alicja
AU - Patricia Rojas, Damaris
AU - Zerini, Dario
AU - Fodor, Cristiana
AU - Viola, Anna
AU - Fanetti, Giuseppe
AU - Volpe, Stefania
AU - Luraschi, Rosa
AU - Bazani, Alessia
AU - Rondi, Elena
AU - Cattani, Federica
AU - Vavassori, Andrea
AU - Garibaldi, Cristina
AU - Alessi, Sarah
AU - Pricolo, Paola
AU - Petralia, Giuseppe
AU - Cozzi, Gabriele
AU - De Cobelli, Ottavio
AU - Musi, Gennaro
AU - Orecchia, Roberto
AU - Marvaso, Giulia
AU - Ciardo, Delia
PY - 2019/1/1
Y1 - 2019/1/1
N2 - objective: To evaluate high-precision external beam reirradiation (re-EBRT) for local relapse of prostate cancer (PCa) after radiotherapy. Methods: This retrospective study included patients with biochemical failure and evidence of isolated local recurrence of PCa after radical/salvage EBRT or brachytherapy that received salvage stereotactic body radiation therapy (SBRT, re-EBRT). Biopsy was not mandatory if all diagnostic elements were univocal (prostate specific antigen evolution, choline-positron emission tomography or magnetic resonance imaging). Salvage SBRT (re-EBRT) was delivered with image-guided radiation therapy (RapidArc®, VERO® and CyberKnife®). results: Data of 64 patients were included, median age at salvage SBRT was 73.2 years, median pre-salvage SBRT prostate specific antigen was 3.89 ng ml −1 . Median total dose was 30 Gy in five fractions, biologically effective dose (BED) of 150 Gy. One acute G3 genitourinary event and one late G3 genitourinary event were observed. No G ≥ 3 bowel toxicity was registered. At the median follow-up of 26.1 months, tumor progression was observed in 41 patients (64%). 18 patients (28%) experienced local relapse. 2-year local control, biochemical and clinical relapse free survival rates were 75, 40 and 53%, respectively. With BED ≥130 Gy 1-year biochemical and clinical progression-free survival rate were 85 and 90%, respectively. conclusions: Salvage SBRT (re-EBRT) for isolated local PCa recurrence is a safe, feasible and noninvasive salvage treatment. Further investigation is warranted to define the optimal patient selection, dose and volume parameters. advances in knowledge: Salvage SBRT reirradiation for the locally recurrent PCa offer a satisfactory tumor control and excellent toxicity profile, if BED ≥130 Gy is administered.
AB - objective: To evaluate high-precision external beam reirradiation (re-EBRT) for local relapse of prostate cancer (PCa) after radiotherapy. Methods: This retrospective study included patients with biochemical failure and evidence of isolated local recurrence of PCa after radical/salvage EBRT or brachytherapy that received salvage stereotactic body radiation therapy (SBRT, re-EBRT). Biopsy was not mandatory if all diagnostic elements were univocal (prostate specific antigen evolution, choline-positron emission tomography or magnetic resonance imaging). Salvage SBRT (re-EBRT) was delivered with image-guided radiation therapy (RapidArc®, VERO® and CyberKnife®). results: Data of 64 patients were included, median age at salvage SBRT was 73.2 years, median pre-salvage SBRT prostate specific antigen was 3.89 ng ml −1 . Median total dose was 30 Gy in five fractions, biologically effective dose (BED) of 150 Gy. One acute G3 genitourinary event and one late G3 genitourinary event were observed. No G ≥ 3 bowel toxicity was registered. At the median follow-up of 26.1 months, tumor progression was observed in 41 patients (64%). 18 patients (28%) experienced local relapse. 2-year local control, biochemical and clinical relapse free survival rates were 75, 40 and 53%, respectively. With BED ≥130 Gy 1-year biochemical and clinical progression-free survival rate were 85 and 90%, respectively. conclusions: Salvage SBRT (re-EBRT) for isolated local PCa recurrence is a safe, feasible and noninvasive salvage treatment. Further investigation is warranted to define the optimal patient selection, dose and volume parameters. advances in knowledge: Salvage SBRT reirradiation for the locally recurrent PCa offer a satisfactory tumor control and excellent toxicity profile, if BED ≥130 Gy is administered.
UR - http://www.scopus.com/inward/record.url?scp=85060554743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060554743&partnerID=8YFLogxK
U2 - 10.1259/bjr.20180494
DO - 10.1259/bjr.20180494
M3 - Article
C2 - 30379566
AN - SCOPUS:85060554743
VL - 92
JO - British Journal of Radiology
JF - British Journal of Radiology
SN - 0007-1285
IS - 1094
M1 - 20180494
ER -